OncoSec Medical (ONCS) Stock Rating Lowered by ValuEngine

OncoSec Medical (NASDAQ:ONCS) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Several other analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of OncoSec Medical in a report on Thursday, November 9th. Maxim Group restated a “buy” rating and issued a $5.00 price objective on shares of OncoSec Medical in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $5.33.

Shares of OncoSec Medical (ONCS) opened at $2.07 on Friday. OncoSec Medical has a twelve month low of $0.88 and a twelve month high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). equities analysts expect that OncoSec Medical will post -0.86 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “OncoSec Medical (ONCS) Stock Rating Lowered by ValuEngine” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/03/oncosec-medical-oncs-stock-rating-lowered-by-valuengine.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

What are top analysts saying about OncoSec Medical Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OncoSec Medical Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit